Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calverley, P. M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calverley, P. M. A.
(Chest. 2000;117:67S-69S.)
© 2000 American College of Chest Physicians

The Future for Tiotropium*

Peter M. A. Calverley, MD

* From the University Hospital, Aintree, Liverpool, UK.

Correspondence to: Peter M. A. Calverley, MD, Pulmonary and Rehabilitation Research group, University Clinical Department at Aintree, University Hospital Aintree, Longmoor Lane, Liverpool, L9 7AL, UK; email: PMACAL{at}liverpool.ac.uk

In spite of growing interest in and knowledge about the causes and progression of COPD, neither the assessment nor pharmacologic treatment of this condition is currently ideal. Tiotropium is the first new treatment for COPD in many years. Tiotropium is a long-acting anticholinergic agent that has a potential role as a once-daily maintenance treatment, and a picture of its effectiveness is gradually emerging. Spirometry data from clinical studies demonstrate that it is a potent bronchodilator in patients with COPD and it is very well tolerated. Further data on health status and quality of life are awaited.

Key Words: anticholinergic agents • bronchodilator therapy • COPD • health-related quality of life • tiotropium






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Chest Physicians.